Abstract
The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Current Drug Targets
Title:A New “Era” for the α7-nAChR
Volume: 13 Issue: 5
Author(s): Patrizia Russo, Alessio Cardinale, Hildegard Shuller
Affiliation:
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Abstract: The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Export Options
About this article
Cite this article as:
Patrizia Russo, Alessio Cardinale, Hildegard Shuller , A New “Era” for the α7-nAChR , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398946
DOI https://dx.doi.org/10.2174/138945012800398946 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Editorial [ Hot Topic:Biology in Anticancer Treatment (Guest Editor: Bruno Vincenzi)]
Current Cancer Drug Targets The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials
Anti-Cancer Agents in Medicinal Chemistry Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening C75, a Fatty Acid Synthase (FAS) Inhibitor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker
Combinatorial Chemistry & High Throughput Screening Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry subject Index To Volume 1
Current Molecular Medicine Toxicological Aspects of Carbon Nanotubes, Fullerenes and Graphenes
Current Pharmaceutical Design Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Role of α7-Nicotinic Acetylcholine Receptor in Normal and Cancer Stem Cells
Current Drug Targets